D.E. Shaw & Co
ADCT icon

D.E. Shaw & Co’s ADC Therapeutics ADCT Stock Holding History

D.E. Shaw & Co’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$770K Buy
719,320
+476,144
+196% +$1.39M ﹤0.01% 3929
2026
Q1 		$912K Sell
243,176
-19,895
-8% -$78.4K ﹤0.01% 3499
2025
Q4 		$929K Buy
+263,071
New +$1.07M ﹤0.01% 3596
2024
Q4 		– Sell
-284,243
Closed -$895K – 4357
2024
Q3 		$895K Buy
284,243
+20,531
+8% +$64.7K ﹤0.01% 3357
2024
Q2 		$833K Buy
263,712
+236,791
+880% +$941K ﹤0.01% 3298
2024
Q1 		$121K Buy
+26,921
New +$99.3K ﹤0.01% 3991
2020
Q4 		– Sell
-27,713
Closed -$914K – 3872
2020
Q3 		$914K Buy
+27,713
New +$1.2M ﹤0.01% 2918

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co's ADCT Position: Q2 2026 in Review

D.E. Shaw & Co increased its ADC Therapeutics (ADCT) stake by 196% in Q2 2026, buying an estimated $1.39M and bringing the position to 719,320 shares worth $770K. The position accounts for ﹤0.01% of the portfolio, ranked #3929.

D.E. Shaw & Co first reported a position in ADCT in Q3 2020 and has held it in 7 quarters since. The position peaked at $929K in Q4 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • D.E. Shaw & Co held 719,320 shares of ADC Therapeutics worth $770K as of Q2 2026.
  • D.E. Shaw & Co bought 476,144 ADC Therapeutics shares in Q2 2026, an estimated $1.39M.
  • ADC Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3929 holding.
  • D.E. Shaw & Co first reported a position in ADC Therapeutics in Q3 2020 and has held it in 7 quarters since.
  • D.E. Shaw & Co's ADC Therapeutics position peaked at $929K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.